Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVAIL platform study in chronic hepatitis B
2024-513176-17-00Phase 2Completed
- Sponsor
- Vir Biotechnology
- Start
- Mar 2023
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2 trial of tobevibart, elebsiran, interferon alfa and tenofovir disoproxil fumarate in Chronic Hepatitis B (CHB) (4 arms), sponsored by Vir Biotechnology. Started Mar 2023; status: completed.
02
Drugs
tobevibartelebsiraninterferon alfatenofovir disoproxil fumarate
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2024-513176-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513176-17-00.